Literature DB >> 1723377

Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

P A Todd1, D Faulds.   

Abstract

Ofloxacin is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. In vitro it has a broad spectrum of activity against aerobic Gram-negative and Gram-positive bacteria, although it is poorly active against anaerobes. Ofloxacin, unlike most other broad spectrum antibacterial drugs, can be administered orally as well as intravenously. Penetration into body tissues and fluids is highly efficient. Clinical trials with orally and intravenously administered ofloxacin have confirmed its potential for use in a wide range of infections, where it has generally proved as effective as standard treatments. Ofloxacin in well tolerated, and in comparison with other available fluoroquinolones is less likely to cause clinically relevant drug interactions. Ofloxacin thus offers a valuable oral treatment (with an option for intravenous administration if necessary) for use in a wide range of clinical infections, but with a particular advantage in more severe or chronic infections when recourse to parenteral broad spectrum agents would normally be required, thereby providing cost savings and additionally allowing outpatient treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723377     DOI: 10.2165/00003495-199142050-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  353 in total

Review 1.  Development of clinically important resistance to quinolones and other antibiotic groups.

Authors:  H Lode
Journal:  J Int Med Res       Date:  1990       Impact factor: 1.671

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  [Efficacy and tolerability of intravenous ofloxacin. A French multicenter study of 273 patients].

Authors:  O Leroy; C Beuscart; B Sivery; E Senneville; Y Mouton
Journal:  Presse Med       Date:  1989 Dec 16-23       Impact factor: 1.228

4.  Single doses of ofloxacin in uncomplicated gonorrhoea.

Authors:  J Aznar; R Prados; A Herrera; A Rodriguez-Pichardo; E J Perea
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  [Efficacy of injectable ofloxacin in treating septicemia. Multicenter study].

Authors:  T Doco-Lecompte; J Modaï
Journal:  Pathol Biol (Paris)       Date:  1989-05

6.  Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study.

Authors:  G Acocella; A Bertrand; J Beytout; J B Durrande; J A Garcia Rodriguez; J Kosmidis; M Micoud; M Rey; M Rodriguez Zapata; J Roux
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

7.  Penetration of ciprofloxacin and ofloxacin into human allograft pancreatic juice.

Authors:  C Brattström; A S Malmborg; G Tydén
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

8.  [Studies of clinical efficacy of ofloxacin against male urethritis caused by Chlamydia trachomatis].

Authors:  T Matsuda; K Okada; O Yoshida
Journal:  Hinyokika Kiyo       Date:  1988-03

9.  The pharmacokinetics and tissue penetration of the fluoroquinolones.

Authors:  M G Bergeron
Journal:  Clin Invest Med       Date:  1989-02       Impact factor: 0.825

10.  Topical chemotherapy in human periodontitis using a new controlled-release insert containing ofloxacin. I. Microbiological observation.

Authors:  S Kimura; H Toda; Y Shimabukuro; M Kitamura; N Fujimoto; Y Miki; H Okada
Journal:  J Periodontal Res       Date:  1991-01       Impact factor: 4.419

View more
  20 in total

1.  Penetration of topical, oral, and combined administered ofloxacin into the subretinal fluid.

Authors:  O Cekiç; C Batman; U Yasar; Y Totan; N E Basci; A Bozkurt; O Zilelioglu; S O Kayaalp
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

2.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

3.  Penetration of gentamicin and ofloxacin in human vitreous after systemic administration.

Authors:  H Verbraeken; A Verstraete; E Van de Velde; G Verschraegen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

4.  Antimicrobial activity of human pancreatic juice and its interaction with antibiotics.

Authors:  E B Minelli; A Benini; C Bassi; H Abbas; M Falconi; F Locatelli; R de Marco; P Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Empirical antibiotic treatment of sepsis in non-neutropenic patients: single agent or combination therapy?

Authors:  M Extermann; C Regamey
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

6.  Levofloxacin in patients with severe respiratory tract infection.

Authors:  S Odagiri
Journal:  Drugs       Date:  1995       Impact factor: 9.546

7.  Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.

Authors:  A W Sufarlan; B M Zainudin; S Pit; I Ishak
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.

Authors:  S Kawahara; Y Watanabe; Y Matsuka; T Sato; K Takahashi
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 9.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 10.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.